IP Library Granted Patent US 7,670,837
Granted Patent B2
US 7,670,837 · App. 11/304,589 · Granted Mar 2, 2010

Non-tumorigenic MDCK cell line for propagating viruses

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,670,837
App. No.
11/304,589
Granted
Mar 2, 2010
Kind
B2
Abstract

The present invention provides novel MDCK-derived adherent non-tumorigenic cell lines that can be grown in the presence or absence of serum. The cell lines of the present invention are useful for the production of vaccine material (e.g., viruses). More specifically, the cell lines of the present invention are useful for the production of influenza viruses in general and ca/ts influenza viruses in particular. The invention further provides methods and media formulations for the adaptation and cultivation of MDCK cells such that they remain non-tumorigenic. Additionally, the present invention provides methods for the production of vaccine material (e.g., influenza virus) in the novel cell lines of the invention.

Claims (8)

1. A cell culture composition comprising non-tumorigenic MDCK cells, wherein said non-tumorigenic MDCK cells are of the MDCK-SF 103 cell line deposited as ATCC Accession Number PTA-6503.

2. A non-tumorigenic MDCK cell line selected from the group consisting of: MDCK-S deposited as ATCC Accession Number PTA-6500; and MDCK-SF 103 deposited as ATCC Accession Number PTA-6503.

3. The cell culture composition of claim 1 , wherein said non-tumorigenic MDCK cells are non-tumorigenic in an adult nude mouse model.

4. The cell culture composition of claim 1 , wherein said non-tumorigenic MDCK cells remain non-tumorigenic after at least 20 passages.

5. The non- tumorigenic MDCK cell line of claim 2 , wherein said cell line is MDCK-S deposited as ATCC Accession Number PTA-6500.

6. The non- tumorigenic MDCK cell line of claim 2 , wherein said cell line is MDCK-SF 103 deposited as ATCC Accession Number PTA-6503.

7. The non- tumorigenic MDCK cell line of claim 2 , wherein said cell line is non-tumorigenic in an adult nude mouse model.

8. The non- tumorigenic MDCK cell line of claim 2 , wherein said cell line remains non-tumorigenic after at least 20 passages.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Oct 26, 2021
From: CIBC BANK USA
To: COSMIC PET LLC (F/K/A HYPER PET LLC); PAWS MERGER PARENT, LLC; COSMIC PET BRANDS LLC (F/K/A HYPER PET BRANDS LLC); OURPET'S COMPANY; VIRTU COMPANY; SMP COMPANY, INCORPORATED; PET FUSION LLC; GRAC HOLDINGS LLC
Reel/Frame 057923/0356 →
RELEASE OF SECURITY INTEREST Recorded Oct 26, 2021
From: CENTERFIELD CAPITAL PARTNERS III, L.P.; CCP III-A, L.P.; CCP III-SBIC, L.P.
To: COSMIC PET LLC (F/K/A HYPER PET LLC); PAWS MERGER PARENT, LLC; COSMIC PET BRANDS LLC (F/K/A HYPER PET BRANDS LLC); OURPET'S COMPANY; VIRTU COMPANY; SMP COMPANY, INCORPORATED; PET FUSION LLC; GRAC HOLDINGS LLC
Reel/Frame 057923/0582 →
ACKNOWLEDGEMENT OF SECURITY INTEREST IN PATENTS Recorded Mar 28, 2019
From: HYPER PET LLC; PAWS MERGER PARENT, LLC; HYPER PET BRANDS LLC; GRAC HOLDINGS LLC
To: CENTERFIELD CAPITAL PARTNERS III, L.P.; CCP III-A, L.P.; CCP III-SBIC, L.P.
Reel/Frame 048725/0677 →
ACKNOWLEDGEMENT OF SECURITY INTEREST IN PATENTS Recorded Dec 21, 2018
From: HYPER PET LLC; PAWS MERGER PARENT, LLC; HYPER PET BRANDS LLC; GRAC HOLDINGS LLC
To: CIBC BANK USA
Reel/Frame 048025/0584 →
CHANGE OF NAME Recorded Oct 23, 2008
From: MEDIMMUNE VACCINES
To: MEDIMMUNE, INC.
Reel/Frame 021727/0797 →
CHANGE OF NAME Recorded Oct 23, 2008
From: MEDIMMUNE, INC.
To: MEDIMMUNE, LLC
Reel/Frame 021730/0202 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 17, 2006
From: SCHWARTZ, RICHARD; BERRY, JOHN M.; SUBRAMANIAN, AJIT; SHI, XIAO
To: MEDIMMUNE VACCINES, INC.
Reel/Frame 018399/0976 →